SECARNA Trademark
Trademark Overview
On Wednesday, January 19, 2022, a trademark application was filed for SECARNA with the United States Patent and Trademark Office. The USPTO has given the SECARNA trademark a serial number of 79340689. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, May 9, 2023. This trademark is owned by Secarna Pharmaceuticals GmbH & Co. KG. The SECARNA trademark is filed in the Computer & Software Services & Scientific Services, Personal and Legal & Social Services categories with the following description:
Granting of licenses to others in industrial property rights in the field of scientific research services in the field of biochemistry, except for the field of cell culture products, scientific research services in the field of nucleic acids and bioinformatics, in particular molecular-biological work methods, especially antisense technology, design of pharmaceutical active ingredients by means of the aforesaid methods and technologies, also using techniques of bioinformatics and development of pharmaceutical products by means of the aforesaid methods and technologies, also using techniques of bioinformatics, including carrying out associated test and diagnostic methods
Scientific research services in the field of biochemistry, except for the field of cell culture products; Scientific research services in the field of nucleic acids and bioinformatics, in particular molecular- biological work methods, especially antisense technology; design of pharmaceutical active ingredients by means of the aforesaid methods and technologies, also using techniques of bioinformatics; development of pharmaceutical products by means of the aforesaid methods and technologies, also using techniques of bioinformatics, including carrying out associated test and diagnostic methods; information technology (IT) consultancy services for the pharmaceutical and biotechnological industry; consultancy for others in the field of biochemistry and nucleic acids and bioinformatics, including antisense technology, with respect to the development of pharmaceutical products; safety and efficacy testing consultancy for others with respect to the evaluation of safety and efficacy of pharmac...
General Information
| Serial Number | 79340689 |
| Word Mark | SECARNA |
| Filing Date | Wednesday, January 19, 2022 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Tuesday, May 9, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Granting of licenses to others in industrial property rights in the field of scientific research services in the field of biochemistry, except for the field of cell culture products, scientific research services in the field of nucleic acids and bioinformatics, in particular molecular-biological work methods, especially antisense technology, design of pharmaceutical active ingredients by means of the aforesaid methods and technologies, also using techniques of bioinformatics and development of pharmaceutical products by means of the aforesaid methods and technologies, also using techniques of bioinformatics, including carrying out associated test and diagnostic methods |
| Goods and Services | Scientific research services in the field of biochemistry, except for the field of cell culture products; Scientific research services in the field of nucleic acids and bioinformatics, in particular molecular- biological work methods, especially antisense technology; design of pharmaceutical active ingredients by means of the aforesaid methods and technologies, also using techniques of bioinformatics; development of pharmaceutical products by means of the aforesaid methods and technologies, also using techniques of bioinformatics, including carrying out associated test and diagnostic methods; information technology (IT) consultancy services for the pharmaceutical and biotechnological industry; consultancy for others in the field of biochemistry and nucleic acids and bioinformatics, including antisense technology, with respect to the development of pharmaceutical products; safety and efficacy testing consultancy for others with respect to the evaluation of safety and efficacy of pharmaceutics; evaluation of pharmaceutical products with respect to their safety and efficacy to assure compliance with industry standards |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Secarna Pharmaceuticals GmbH & Co. KG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | DE |
Trademark Events
| Event Date | Event Description |
| Tuesday, May 9, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, May 8, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, May 8, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, February 7, 2023 | REFUSAL PROCESSED BY IB |
| Tuesday, January 17, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, January 17, 2023 | REFUSAL PROCESSED BY MPU |
| Tuesday, January 17, 2023 | ASSIGNED TO EXAMINER |
| Monday, November 7, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Sunday, November 6, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, October 28, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, May 24, 2022 | APPLICATION FILING RECEIPT MAILED |
| Friday, May 20, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, May 19, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
